Edgewise Therapeutics (EWTX) Insider Trading & Ownership $14.87 +0.08 (+0.54%) As of 05/20/2025 04:00 PM Eastern Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Edgewise Therapeutics (NASDAQ:EWTX) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage23.20%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$10.00 MNumber OfInsiders Selling(Last 12 Months)6Amount OfInsider Selling(Last 12 Months)$12.73 M Get EWTX Insider Trade Alerts Want to know when executives and insiders are buying or selling Edgewise Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address EWTX Insider Buying and Selling by Quarter Edgewise Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails5/2/2025Alan J RussellInsiderSell1,551$16.45$25,513.95 5/2/2025Joanne M DonovanCMOSell5,187$16.45$85,326.15 5/2/2025John R MooreGeneral CounselSell1,930$16.45$31,748.50 5/2/2025Kevin KochCEOSell4,276$16.45$70,340.20 5/2/2025R Michael CarruthersCFOSell1,314$16.45$21,615.30 4/3/2025Orbimed Advisors LlcDirectorBuy496,771$20.13$10,000,000.23 2/6/2025Alan J RussellInsiderSell1,200$30.13$36,156.00 2/5/2025Kevin KochCEOSell8,636$30.03$259,339.08 1/28/2025Joanne M DonovanCMOSell25,000$27.63$690,750.00 12/30/2024Alan J RussellInsiderSell100,000$27.37$2,737,000.00 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 12/24/2024Marc SemigranInsiderSell29,709$29.69$882,060.21 9/23/2024John R MooreGeneral CounselSell20,922$27.63$578,074.86 9/20/2024Alan J RussellInsiderSell75,000$28.27$2,120,250.00 9/20/2024Joanne M DonovanCMOSell7,162$28.29$202,612.98 9/20/2024John R MooreGeneral CounselSell50,000$28.37$1,418,500.00 9/20/2024R Michael CarruthersCFOSell125,092$28.57$3,573,878.44 (Data available from 1/1/2013 forward) EWTX Insider Trading Activity - Frequently Asked Questions Who is on Edgewise Therapeutics's Insider Roster? The list of insiders at Edgewise Therapeutics includes Alan J Russell, Behrad Derakhshan, Holdings A/S Novo, Joanne M Donovan, John R Moore, Jonathan C Fox, Kevin Koch, Marc Semigran, Orbimed Advisors Llc, Peter A Thompson, and R Michael Carruthers. Learn more on insiders at EWTX. What percentage of Edgewise Therapeutics stock is owned by insiders? 23.20% of Edgewise Therapeutics stock is owned by insiders. Learn more on EWTX's insider holdings. Which Edgewise Therapeutics insiders have been buying company stock? The following insiders have purchased EWTX shares in the last 24 months: Jonathan C Fox ($100,970.10), Orbimed Advisors Llc ($10,000,000.23), and Peter A Thompson ($4,999,995.00). How much insider buying is happening at Edgewise Therapeutics? Insiders have purchased a total of 962,173 EWTX shares in the last 24 months for a total of $15,100,965.33 bought. Which Edgewise Therapeutics insiders have been selling company stock? The following insiders have sold EWTX shares in the last 24 months: Alan J Russell ($6,529,138.00), Behrad Derakhshan ($124,533.38), Joanne M Donovan ($1,048,315.75), John R Moore ($2,065,311.32), Kevin Koch ($389,283.60), Marc Semigran ($882,060.21), and R Michael Carruthers ($5,056,482.61). How much insider selling is happening at Edgewise Therapeutics? Insiders have sold a total of 771,348 Edgewise Therapeutics shares in the last 24 months for a total of $16,704,863.66 sold. Edgewise Therapeutics Key ExecutivesDr. Peter A. Thompson FACP (Age 64)M.D., Co-Founder & Independent Chairman Compensation: $76kDr. Kevin Koch Ph.D. (Age 64)President, CEO & Director Compensation: $905.52kDr. Badreddin Edris Ph.D. (Age 37)Co-Founder & Independent Director Compensation: $43kDr. Behrad Derakhshan Ph.D. (Age 44)Chief Business Officer Compensation: $630.67kDr. Joanne M. Donovan M.D. (Age 67)Ph.D., Chief Medical Officer Compensation: $696.4kDr. Alan J. Russell Ph.D. (Age 54)Co-Founder, Chief Scientific Officer & Director Compensation: $657.52kMr. R. Michael Carruthers (Age 66)Chief Financial Officer Compensation: $386.01k1 recent tradesMr. John R. Moore (Age 60)General Counsel 1 recent tradesDr. Marc Semigran M.D. (Age 67)Chief Development Officer More Insider Trading Tools from MarketBeat Related Companies VRNA Insider Ownership LNTH Insider Ownership AXSM Insider Ownership TGTX Insider Ownership GRFS Insider Ownership NUVL Insider Ownership ADMA Insider Ownership PCVX Insider Ownership KRYS Insider Ownership CYTK Insider Ownership Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles UnitedHealth Insiders Double Down: Is UNH Stock a Value Play?Sprouts Stock: Insider Sales, But Strong Bullish Signals5 Hot Small-Cap Insiders Bought at the Peak of Tariff FearsThe Top-Ranked Insider Buys From April by Market CapMcDonald’s Insiders Sell Shares! Investors Should Do the Opposite This page (NASDAQ:EWTX) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edgewise Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Edgewise Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
